Vall d'Hebron participates in a clinical trial to evaluate the efficacy and safety of low-dose selinexor in patients with severe COVID-19

The study will measure the time to clinical improvement of the patients, but will also include the mortality rate after 28 days, the percentage of patients who have required mechanical ventilation or ICU admission, among other parameters.

26/04/2020

Vall d'Hebron Barcelona Hospital Campus is leading a clinical trial promoted by Karyopharm Therapeutics that will study the effects of selinexor, a drug indicated to treat cancer, in patients with severe COVID-19. Vall d'Hebron is one of only two participating centers in Spain and we have already included the first patient. The other center is the Hospital de Salamanca and in the next few days new hospitals from around the world will be added.

Dr. Benito Almirante, head of the Infectious Diseases Service of the Vall d'Hebron Hospital and head of the research group on Infectious Diseases of the Vall d'Hebron Research Institute (VHIR) will be responsible for coordinating the clinical trial.

This is a randomized, single-blind, phase II trial that will assess the activity and safety of low-dose oral selinexor (KPT-330) in patients with severe COVID-19 infection. 230 patients will be recruited.

Patients who will undergo this treatment are in an urgent clinical situation after a diagnosis of COVID-19 confirmed by PCR and must be over 18 years of age.

The study will measure the time to clinical improvement evaluating clinical aspects such as the absence of fever for 24 hours without the need for antipyretics (paracetamol), an oxygen saturation greater than or equal to 94% without oxygen support, or a respiratory rate less than or equal to at 24 breaths per minute, among other parameters.

On the other hand, other aspects such as the mortality rate after 28 days, the percentage of patients who have required mechanical ventilation or admission to the ICU, the general evolution of patients according to age (older or younger than 70 years) will also be included.

In the same way, the anti-inflammatory and immune effects of selinexor will be analyzed, as well as its tolerability and safety at low doses to determine the capacity of this drug to modify the course of the disease.

Share it:
Professionals relacionats

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vhebron.net, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.